Acadian Asset Management
NTLA icon

Acadian Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Acadian Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Buy
+2,607
New +$33.2K ﹤0.01% 1902
2021
Q1 		– Sell
-583
Closed -$32K – 2237
2020
Q4 		$32K Buy
+583
New +$21.2K ﹤0.01% 2052
2017
Q3 		– Sell
-74,230
Closed -$1.19M – 1490
2017
Q2 		$1.19M Sell
74,230
-21,923
-23% -$306K 0.01% 673
2017
Q1 		$1.35M Buy
+96,153
New +$1.29M 0.01% 710

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management's NTLA Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 2,607 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1902 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in NTLA as recently as Q4 2020.

Acadian Asset Management first reported a position in NTLA in Q1 2017 and has held it in 4 quarters since. The position peaked at $1.35M in Q1 2017. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Acadian Asset Management held 2,607 shares of Intellia Therapeutics worth $32K as of Q1 2026.
  • Intellia Therapeutics was a new Acadian Asset Management position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1902 holding.
  • Acadian Asset Management first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 4 quarters since.
  • Acadian Asset Management's Intellia Therapeutics position peaked at $1.35M in Q1 2017.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.